Cepheid Receives CE-IVD Clearance for Xpert HCV VL Fingerstick

Enables Hepatitis C Point-of-Care molecular testing and linkage to care

SUNNYVALE, Calif., Sept. 19, 2018 /PRNewswire/ -- Cepheid today announced the CE-IVD marking of Xpert HCV VL Fingerstick, the first molecular test to detect and quantify hepatitis C Virus (HCV) RNA levels directly from a fingerstick blood sample. Currently, the clinical care pathway for detection of hepatitis C faces many barriers, including complicated multi-step diagnostic algorithms based on antibody screening and RNA confirmation. These algorithms currently require centralized testing technologies that may result in treatment delays and loss to follow up, and could discourage at-risk populations from accessing testing and receiving care.

"Over the past few years, Cepheid, with its collaborators at the Kirby Institute and FIND have been able to demonstrate that a rapid and accurate test for active HCV infection can be performed on a drop of blood," said David H. Persing, M.D., Ph.D., Cepheid's Chief Medical and Technology Officer. "This is the first HCV RNA detection technology sensitive enough for both active case finding and use as a potential test of cure at the point of care."

Cepheid's Xpert HCV VL Fingerstick test allows for a simplified diagnostic pathway. From blood collected into a capillary tube via fingerstick, the simple to use test detects and quantifies a wide range of HCV genotypes within 58 minutes. This enables diagnosis of HCV and initiation of direct acting antiviral treatment within a single clinic visit, and with this, the potential for curing more people with HCV.

The new test is now available in the EU and all countries recognizing the CE-mark.

About Cepheid
Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit www.cepheid.com.

For Cepheid Media Inquiries: 
Darwa Peterson 

Web Site: http://www.cepheid.com

Download Spec Sheet

More from Packaging Products & Equipment

All Topics